|
FY2026
12 months to Mar 31, 2026
|
FY2025
12 months to Mar 31, 2025
|
FY2024
12 months to Mar 31, 2024
|
FY2023
12 months to Mar 31, 2023
|
FY2022
12 months to Mar 31, 2022
|
|
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of sales | |||||
| Gross profit | |||||
| Research and development expenses | |||||
| Selling, general and administrative expenses | |||||
| Other (gains) and losses | |||||
| Share of after-tax profit of equity accounted investees | |||||
| Restructuring, integration and acquisition costs | |||||
| Impairment of goodwill | |||||
| Gain on remeasurement of previously held equity interest | |||||
| Operating income | |||||
| Finance expense – net | |||||
| Earnings before income taxes | |||||
| Income tax expense | |||||
| Net income (loss) from continuing operations | |||||
| Net income from discontinued operations | |||||
| Net income | |||||
| Attributable to: | |||||
| Equity holders of the Company | |||||
| Non-controlling interests | |||||
| Earnings per share attributable to equity holders of the Company | |||||
| Basic – continuing operations (in Canadian dollars per share) | |||||
| Diluted - continuing operations (in Canadian dollars per share) | |||||
| Basic - discontinued operations (in Canadian dollars per share) | |||||
| Basic (in dollars per share) | |||||
| Diluted (in dollars per share) |
Loading...
